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High-affinity (& N 10 nM) binding sites for nicotine and acetylcholine (ACh) have recently been identified 
in vertebrate brain. It has been suggested that these sites are desensitized ganglionic (C6) nicotinic acetyl- 
choline receptors (nAChRs). We have tested the pheochromocytoma cell line PC 12, which is known to con- 
tain well-expressed C6 nAChRs, to determine if these nAChRs are associated with high-affinity [3H]ACh- 
binding sites. We found that the high-affinity nicotinic [3H]ACh-binding site is absent in PC12 cells. We 
also found that the concentration of nicotine or ACh necessary to desensitize carbamylcholine-stimulated 
Na+ flux was at least two orders of magnitude greater than the concentrations used in binding experiments. 
We conclude that high-affinity nicotinic binding sites are not equivalent o C6 ganglionic receptors. 
Acetylcholine receptor Nicotinic receptor 
1. INTRODUCTION 
A high-affinity nicotinic binding site in mam- 
malian brain has been identified in several 
laboratories using radiolabeled acetylcholine [l] 
and nicotine [2] that has a high affinity for 
cholinergic agonists but not antagonists and, is 
unrelated to the brain a-bungarotoxin (Butx) 
binding component [3,4]. It has been suggested 
that the high affinity of this site is associated with 
a desensitized receptor state that results from the 
use of agonists as ligands [5]. Time-dependent in- 
creases in agonist affinities are known to occur 
with Torpedo [6] and muscle [7] nAChR, and this 
phenomenon reconciles the apparent discrepancy 
between agonist binding constants measured by 
Abbreviations: ACh, acetylcholine; DFP, diisopropyl 
fluorophosphate; nAChR, nicotinic acetylcholine 
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equilibrium methods and the much higher concen- 
trations known to be necessary for channel activa- 
tion. 
Two kinds of mammalian nAChRs have been 
characterized by electrophysiological techniques. 
Those found at the neuromuscular synapse are 
blocked by Butx. Nicotinic receptors insensitive to 
Butx and several other neurotoxins are found at 
the spinal Renshaw synapse and at several 
ganglionic synapses (review [8]). These nAChRs 
are termed ganglionic or C6 receptors. Since the 
binding of nicotine and ACh to high-affinity sites 
is not displaced by Butx, it is possible that these 
receptor sites are C6 nAChRs. Although elec- 
trophysiological studies are not in complete agree- 
ment, ganglionic blockers such as mecamylamine 
typically antagonize central nicotinic cholinergic 
activity [9], suggesting that at least some brain 
nAChRs have characteristics of C6 receptors. 
To test the hypothesis that C6 receptors and 
high-affinity nicotinic [3H]ACh-binding sites are 
equivalent, we measured high-affinity [3H]ACh 
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binding to the clonal sympathomimetic PC12 cell 
line, which is known to express nAChRs that have 
been extensively characterized in Na+ flux ex- 
periments as C6 receptors [lo-121. We also deter- 
mined the concentrations of ACh and nicotine 
necessary to activate and desensitize PC12 cells in 
order to assess whether the concentration of ACh 
or nicotine used in binding studies would be suffi- 
cient to produce desensitization. 
2. MATERIALS AND METHODS 
2.1. [JH]ACh-binding assay 
The concentration of [3H]ACh-binding sites was 
determined by a modification of the method of 
Schwartz et al. [l] as described by Larsson et al. 
[13]. Rats were decapitated and the brains rapidly 
removed. Individual brain areas were rapidly 
dissected, frozen in liquid nitrogen, and stored at 
-70°C. Brain membranes were prepared by 
repeated (3 x ) homogenization and centrifugation 
(39OOOxg, 10 min) in ice-cold buffer containing 
50 mM Tris, 120 mM NaCl, 5 mM KCl, 2 mM 
CaC12, 1 mM MgCL, and 1.5 ,uM atropine. PC12 
cells were prepared in the same manner except that 
some were homogenized between centrifugations 
and some were sonicated between centrifugations. 
All samples were incubated in 100 pM DFP for 20 
min prior to assay. 
Tissue samples (500-700 /cg protein in a volume 
of 200 ~1) were incubated with 10 nM [‘H]ACh, 
synthesized from choline (New England Nuclear, 
spec. act. 80 Ci/mmol) as described by Schwartz et 
al. [l], for 45 min at 2°C in a total of 500~1 buffer. 
Non-specific binding was determined by adding 
carbamylcholine to control tubes. 
2.2. Flux experiments 
Ion flux experiments were carried out in buffer 
containing 0.8 &i/ml 22Na+ (Amersham, spec. 
act. 13 500 Ci/mol), 2 mM carbamylcholine, and 5 
mM ouabain. Cells were incubated for 1 min at 
25’C, then rapidly rinsed in 3 ice-cold l-l beakers 
of buffer. The control flux obtained in the absence 
of desensitization treatment ranged from 180 to 
260 nmol/mg per min, similar to that reported in 
[lo]. A background flux of approx. 25 nmol/mg 
per min, obtained in the absence of car- 
bamylcholine, was subtracted from all fluxes. 
22Na+ influx exp eriments were done essentially 
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as described by Stallcup [lo]. Cells were desensi- 
tized in buffer containing ACh or nicotine for 40 
min at 25°C. In experiments where ACh was used 
to desensitize the 22Na+ flux, cells were pretreated 
for 20 min with 10m4 M DFP, and 10e4 M DFP 
and 10T4 M neostigmine were added to the incuba- 
tion buffer. 
3. RESULTS AND DISCUSSION 
The PC12 cell line, first developed by Greene 
and Tischler [14] from a rat pheochromocytoma, 
has become an established model for sympathetic 
neurons in culture. PC12 cells express C6 nAChRs 
which are characterized by their insensitivity to 
Butx [l I] and their blockade by the ganglionic an- 
tagonist, mecamylamine [ 121. 
Table 1 shows that PC12 cells do not contain 
high-affinity t3H]ACh-binding sites. To confirm 
the validity of our assay, the amount of high- 
affinity [3H]ACh binding to a number of rat brain 
areas was simultaneously determined. Both the ab- 
solute and relative amounts of high-affinity 
[3H]ACh binding are in essential agreement with 
those reported by Schwartz et al. [ 11. It is not likely 
that our results reflect a site density too low to 
measure in the [3H]ACh-binding assay but still suf- 
ficient to give rise to the observed Na+ flux. The 
concentration of C6 nAChRs in PC12 cells can be 
estimated by the comparison of flux in PC12 cells 
with that of a muscle cell line where the concentra- 
tion of nAChRs can be assayed by [12’I]Butx 
binding. A flux of 380 nmol Na+ /mg protein per 
min and a concentration of 750 fmol nAChRs/ mg 
protein have been measured in BC3H-1 cells [7]. If 
the conductance properties of PC12 nAChRs are 
reasonably similar to muscle nAChRs, then PC12 
cells would be expected to contain approximately 
400 fmol nAChRs/mg protein. This concentration 
of nAChRs is considerably greater than the 
amount of the [‘H]ACh binding in a rat brain 
homogenate and far greater than the limit of sen- 
sitivity of the [‘H]ACh assay, which is about 2 
fmol/mg. 
Early studies that characterized purified [ 151 and 
membrane-associated [ 161 electric fish and electric 
eel nAChR reported very high (& = 2-60 nM) 
binding affinities for ACh. These were several 
orders of magnitude greater than the KO.S (concen- 
tration of agonist required to produce a 50% of 
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Table 1 
The concentration of [3H]ACh nicotinic binding sites in several regions of rat brain and 
PC12 cells 
Tissue N Specific binding Specific binding Data taken from 
(fmol/mg protein, (pmol/griginal Schwartz et al. [6] 
X f SE) wet wt, X f SE) (pmol/g original 
wet wt) 
Thalamus 2 31.4 f 0.08 2.70 + 0.10 2.66 
Cortex 3 30.7 f 0.85~ 2.70 f 0.43 1.61 
Hippocampus 6 18.0 f 2.10 1.40 f 0.17 0.44 
Hypothalamus 2 13.0 + 0.25 0.90 f 0.02 1.05 
Cerebellum 2 11.0 & 0.01 0.72 f 0.09 1,03 
Inferior colliculus 3 9.3 * 0.32 0.68 f 0.04 0.51 
PC12 cells (intact) 2 0 0 0 
PC12 cells (sonicated) 2 0 0 0 
PC12 cells (homogenized) 2 0 0 0 
Liver 0 0 0 
Heat-denatured cortex 2 0 0 0 
N, number of different samples. Each sample was assayed in triplicate as described in 
section 2 
maximum response) values observed in ion flux ex- 
periments [6]. It was ultimately shown that ex- 
posure to agonists resulted in a time-dependent 
increase in the affinity of the receptor for the 
agonist [17]. 
8.2x 10m5 M for ACh. These values are similar to 
those reported for the muscle cell line, BC3H-1, 
where the Kact for nicotine is 2.32 x 10v4 M and the 
Kact for carbamylcholine is 9.49~ lo-’ M [7]. 
When prolonged exposure to agonists causes 
receptors to become desensitized, these receptors 
cannot participate in the mediation of ion flux. 
The concentration dependence of the consequent 
reduction in conductance should then reflect the 
affinity of the desensitized receptor (&cs) for 
agonists. This expectation has been rigorously con- 
firmed by Sine and Taylor [7] in the muscle cell line 
BC3H-1, where Kdcs values were found to agree 
closely with binding constants obtained from 
[1251]Butx competition experiments where the cells 
were pretreated with agonists. We therefore ap- 
plied this strategy to ACh and nicotine-mediated 
ion flux in PC12 cells. Determination of the affini- 
ty of PC12 cell nAChRs for nicotine and ACh by 
this method consequently provided an independent 
means for establishing whether PC12 nAChRs 
have Kdes values in the 10-100 nM range that 
would correspond to high-affinity ACh and 
nicotine sites. 
Fig.1 shows dose-response curves obtained for 
desensitization of carbamylcholine-stimulated 
PC12 Na+ flux by nicotine and acetylcholine. &es 
values obtained in these experiments were 
3.3 x 10m5 M for nicotine and 6.4x 10s5 M for 
ACh. Since these values reflect the affinity of 
desensitized nAChRs for these ligands, we con- 
clude that desensitized PC12 nAChRs do not bind 
ACh or nicotine with affinities consistent with the 
The concentration of agonist necessary to Fig.1. Desensitization f 22Na+ flux in PC12 cells by 
achieve half-maximal activation (Kact) of PC12 ACh (M), and nicotine (x- x). Sodiunh flux ex- 
nAChRs is 7.7x 10T5 M for nicotine and periments were carried out as described in section 2. 
267 
Volume 205, number 2 FEBSLETTERS September 1986 
high-affinity binding sites measured for these 
Iigands in brain. 
We conclude that the C6 nAChRs present in 
PC12 cells do not possess high-affinity binding 
sites for ACh or nicotine and suggest hat high- 
affinity nicotinic ACh and nicotine binding sites 
and C6 nAChRs are not equivalent. The function 
of high-affinity [3H]ACh- and [3H]nicotinic 
binding sites is not known but they are apparently 
pre-synaptic in several areas of mammalian brain 
[3,18]. Clearly, the high-affinity nicotinic recep- 
tors are distinct from the central Butx binding 
component which is a presumed post-synaptic 
nicotinic receptor with binding sites for ACh and 
peripheral antagonists [8,19]. Ganglionic an- 
tagonists do not displace the binding of [3H]ACh, 
[3H]nicotine nor [1251]Butx to neural tissue, sug- 
gesting the possibility of an additional nicotinic 
receptor site. The diversity of receptor subtypes in 
other systems is consistent with the concept that 
multiple forms of nicotinic receptors may exist. 
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